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Abstract 
Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer’s 
disease (AD). This neuronal calcium sensor protein previously used as a marker of acute 
ischemic stroke is elevated in the cerebrospinal fluid (CSF) of AD patients. The goal of this 
study was to assess CSF VILIP-1 potential in early AD diagnosis and in differentiating MCI 
patients with and without risk of AD. Additionally, we tested VILIP-1 ability to differentiate 
AD from other primary causes of dementia, and predict the progression of AD-related 
cognitive decline. VILIP-1 levels were compared with five CSF AD biomarkers (t-tau, Aβ1-
42,p-tau181, p-tau199, and p-tau231). VILIP-1 successfully differentiated two MCI patient groups 
characterized by absence or presence of pathological levels of these CSF biomarkers, except 
for t-tau.VILIP-1/Aβ1-42and VILIP-1/p-tau181ratios also differentiated MCI patients with 
pathological CSF biomarker levels. However, there was no difference in VILIP-1 levels 
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between AD and MCI patients. VILIP-1/Aβ1-42 and VILIP-1/p-tau231 ratios reached high 
sensitivities (above 70%) and very high specificities (above 85%) in differentiating AD 
patients from HC. Additionally, VILIP-1 differentiated AD from patients with Lewy body 
disease with 77.1% sensitivity and 100% specificity. VILIP-1 potential as a prognostic 
biomarker of cognitive decline in AD was also proved since VILIP-1/t-tau, VILIP-1/p-
tau181and VILIP-1/p-tau231ratios correlated with MMSE scores. These data indicate that 
VILIP-1 alone or in combination with other AD CSF biomarkers represent a valuable marker 
for the early diagnosis of AD, recognition of MCI patients at higher risk to develop dementia, 
and in differentiating AD from LBD. 
Keywords: Visinin-like protein 1, dementia, biomarker, mild cognitive impairment, 
Alzheimer’s disease, cerebrospinal fluid, early diagnosis. 
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Aβ1-42, amyloid beta1-42; AD, Alzheimer’s disease; ApoE, apolipoprotein E; AUC, area under 
the curve; CDR, Clinical Dementia Rating; CJD, Creutzfeldt-Jakob disease; CSF, 
cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; FTD, frontotemporal 
dementia; GWAS, genome-wide association studies; HC, healthy control; LBD, Lewy body 
disease; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NCS, 
neuronal calcium sensor; NFT, neurofibrillary tangles; PiB-PET, positron-emission 
tomography with [
11
C]-labeled Pittsburgh Compound-B; PSP, progressive supranuclear palsy; 
p-tau181, tau protein phosphorylated at threonine 181; p-tau199, tau protein phosphorylated at 
serine 199; p-tau231, tau protein phosphorylated at threonine 231; ROC, Receiver Operator 
Characteristic; SP, senile plaques; t-tau, total tau; VaD, vascular dementia; VILIP-1, visinin-
like protein-1. 
Introduction 
A cure for Alzheimer’s disease (AD), the most common cause of dementia, is still not 
available. Numerous potential disease-modifying therapies are currently in preclinical and 
clinical trials. It is crucial to initiate the treatment while the disease is in its early phase. The 
issue is to diagnose AD in asymptomatic individuals, in whom neurodegeneration is not yet 
advanced. This is complicated by the fact that the first AD symptoms occur in patients with 
mild cognitive impairment (MCI) of whom only 12% annually convert to AD [1]. For the 
proper administration of potential therapeutics, it is also important to differentiate AD from 
other primary causes of dementia like vascular dementia (VaD), Lewy body disease (LBD), 
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and frontotemporal dementia (FTD) [2-8]. Promising AD biomarkers, such as neuroimaging 
and cerebrospinal fluid (CSF) biomarkers, still cannot reliably detect the disease at preclinical 
stages [9-11]. However, the results of recent longitudinal studies on cognitively normal 
individuals have been encouraging: AD biomarkers that represent candidates for therapeutic 
trials were detected in asymptomatic individuals [12, 13]. 
Senile plaques (SP) and neurofibrillary tangles (NFT) are major neuropathological 
hallmarks of AD [14, 15]. SP and NFT are composed of amyloid β protein and 
hyperphosphorylated tau protein, respectively. Pathological processes in the brain are 
reflected in the CSF because of the molecular exchange that occurs at the brain/CSF barrier 
[16]. Three CSF biomarkers of AD - amyloid β1-42 (Aβ1-42), total tau (t-tau), and tau protein 
phosphorylated at threonine 181 (p-tau181) - are considered to reflect underlying pathological 
processes in the AD brain. Recently it was proposed that biomarkers of neuronal death would 
reflect disease progression better than markers of disease pathology (Aβ1-42, t-tau, and p-tau) 
[17]. One of the proposed neuronal death biomarkers is visinin-like protein-1 (VILIP-1), a 
neuronal calcium sensor (NCS) protein.VILIP-1, VILIP-2, VILIP-3, neurocalcin δ, and 
hippocalcin constitute one of the five NCS proteins subfamilies, the visinin-like proteins [18, 
19]. Braunewell proposed a mechanism by which Aβ deposition leads to dysregulation of 
calcium homeostasis in AD [20]. In this model, Aβ modulate the expression of NCS proteins 
so that calsenilin is upregulated, while VILIP-1 is downregulated [20]. Additionally, the 
neuroprotective calcium-buffer proteins calretinin and calbindin-D28K are downregulated in 
AD [21]. This imbalance of calcium sensor and buffer proteins ratio makes neurons more 
vulnerable to Aβ-induced calcium-mediated neurotoxicity, as Aβ induces the release of 
calcium from internal stores and enhances external calcium influx [20]. VILIP-1 
overexpression in cellular models induces tau hyperphosphorylation [22]. Understanding 
calcium homeostasis disturbance in AD is important because changes in calcium signaling in 
AD precede neuronal loss, and may serve as a potential therapeutic target in AD [23]. In the 
brains of AD patients, VILIP-1 was detected near NFT and neuritic plaques in the temporal 
cortex and anterior cingulated cortex, and in dystrophic neuritis in the angular gyrus [22, 24]. 
VILIP-3 immunoreactivity was detected near NFT in the entorhinal cortex [24]. Also, recent 
genome-wide association studies (GWAS) showed an association of polymorphisms in 
VILIP-1 and VILIP-3 genes with the occurrence of AD [25, 26]. Altogether, these factors 
may contribute to neuronal cell death and to the increase of VILIP-1 in CSF of AD patients 
[12, 17, 27-30]. VILIP-1 levels were also increased in plasma of AD patients [27]. Recent 
studies reported the diagnostic potential of VILIP-1 in AD detection at early stages and in 
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monitoring of disease progression [17, 28]. However, whether VILIP-1 levels could 
discriminate MCI patients with higher risk of developing AD has not been investigated. 
The scope of this cross-sectional study was to assess 1) CSF VILIP-1 diagnostic 
potential (detection of early AD in MCI patients); 2) VILIP-1 potential in differentiating MCI 
patients into two separate groups (with and without risk of AD); 3) the ability of VILIP-1 to 
differentiate AD from other primary causes of dementia; and 4) VILIP-1 potential as a 
prognostic marker of cognitive decline in AD.  
Materials and methods 
The patients included in this study were recruited at the University Hospital Centre, 
Zagreb and the General Hospital Vinkovci, Croatia. All procedures involving experiments on 
human subjects were done in accord with the approval of the Central Ethical Committee of 
the University of Zagreb Medical School (case no. 380-59/11-500-77/90, class 641-01/11-02 
signed on 19th May 2011) and in accord with the Helsinki Declaration (World Medical 
Association, 2013). Demographic data of all patients and Mini-Mental State Examination 
(MMSE) scores are listed in Table 1. This study included altogether 195 patients of whom109 
fulfilled NINCDS-ADRDA criteria for AD, 9 for VaD, 18 for FTD, 5 for LBD, and 45 for 
MCI [1, 31]. Nine healthy controls (HC) were also included in this study. Patients underwent 
MMSE, and neurological examination [32], complete blood tests including albumin, thyroid 
function, vitamin B12, electrolytes, and VDRL test for syphilis. CSF was obtained by lumbar 
puncture between intervertebral spacesL3/L4 or L4/L5, always between 9 a.m. and 11 a.m. 
Samples were centrifuged for 10 minutes at 2,000 g, aliquoted, and stored at -80°C. 
CSF Aβ1-42, t-tau, and p-tau181 levels were determined using Innotest β-amyloid1-42, Innotest 
hTau Ag, and Innotest Phospho-Tau(181P) ELISA (enzyme-linked immunosorbent assay) kits 
(Fujirebio, Gent, Belgium), respectively. P-tau199, p-tau231, and VILIP-1 CSF levels were 
measured using TAU [pS199] Phospho-ELISA Kit, Human (Life Technologies, Carlsbad, 
CA, USA), Tau [pT231] Phospho-ELISA Kit, Human (Life Technologies, Carlsbad, CA, 
USA), and VILIP-1 Human ELISA (BioVendor, Brno, Czech Republic), respectively.Each 
sample was analyzed in duplicate using all aforementioned ELISA kits. Measurements of 
each biomarker were performed on the same day using the same batch of reagents. Protein 
concentrations were calculated in GraphPad Prism 5.0 software (GraphPad Software, San 
Diego, CA, USA) using a 4-parameter algorithm.The limit of detection of VILIP-1 Human 
ELISA (BioVendor, Brno, Czech Republic) kit is 27 pg/ml (as indicated in the manufacturer's 
protocol). All samples with VILIP-1 levels lower than blank, were assigned the value of 27 
pg/ml since the limit of detection for BioVendor ELISA kit was set at 27 pg/ml. As the 
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BioVendor ELISA kit includes quality controls (including samples with VILIP-1 in high and 
low concentrations), it ensures that the kit is working properly. 
 
CSF biomarker levels were compared using a Student's t-test between groups and were 
mutually correlated using Pearson's correlation. Before statistical analyses we tested data for 
normality using the Kolmogorov-Smirnov test. If the Kolmogorov-Smirnov test did not 
support normality, we used the Mann-Whitney U test and Spearman's correlation for pairwise 
comparisons and for correlations, respectively. Statistical analyses were performed using 
SPSS 19.0.1 (SPSS, Chicago, IL, USA), with the statistical significance set at  = 0.05. 
 
Results 
VILIP-1 in early AD diagnosis and differentiation of AD from other primary causes of 
dementia 
The levels of VILIP-1 measured in AD, MCI, VaD, FTD, LBD patients, and HC, as 
well as demographic data and MMSE scores are summarized in Table 1. Figure 1 shows the 
CSF levels of VILIP-1 in these groups. CSF levels of Aβ1-42, t-tau, p-tau181, p-tau199, and p-
tau231measured in AD, MCI, VaD, FTD, LBD patients, and HC are listed in Table 2. 
VILIP-1 levels were significantly higher in AD patients compared to HC (t = 2.871, df 
= 116, p = 0.005). Also, CSF levels of VILIP-1 were higher in VaD (t = 2.757, df = 16, p = 
0.014). No significant difference in VILIP-1 levels was found between LBD patients and HC 
(U = 20, Z = -0.341, p = 0.733) and FTD and HC patients (t = 1.958, df = 25, p=0.062).When 
patients with FTD, VaD, and LBD were grouped together  as “other dementias” (Figure 1), 
no significant difference in CSF levels of VILIP-1 between HC and “other dementias” group 
was obtained (t = 1.918, df = 39, p = 0.062). 
There was no difference in VILIP-1 CSF levels between AD patients and either VaD 
(t= -0.337, df = 116, p = 0.737) or FTD (t = 1.449, df = 125, p = 0.150) patients. VILIP-1 
levels were lower in LBD than in AD patients (t = 2.869, df = 112, p = 0.005; Figure 1). No 
significant difference in VILIP-1 levels was observed when comparing AD patients to the 
other dementias group (t = 1.736, df = 139, p = 0.085; Figure 1). Using VILIP-1 as a 
biomarker, AD patients were differentiated from VaD patients with 86.2% sensitivity and 
22.2% specificity (area under the curve - AUC = 0.456, p = 0.659), from FTD patients with 
66.1% sensitivity and 55.6% specificity (AUC = 0.592, p = 0.213), and from LBD patients 
with 77.1% sensitivity and 100% specificity (AUC = 0.839, p = 0.01). 
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The CSF concentration of VILIP-1 was significantly higher in AD patients than in 
MCI patients (t = 3.271, df = 150, p = 0.001), while there was no difference in VILIP-1 levels 
between MCI and HC cases (t = 1.190, df = 50, p = 0.240; Figure 1). No difference in VILIP-
1 levels was found when comparing MCI to FTD patients (t = -0.853, df = 59, p = 0.397), 
MCI and LBD patients (U = 86.5, Z = -0.718, p = 0.473), and MCI patients with FTD, VaD, 
and LBD patients grouped together (t = -1.046, df = 73, p = 0.299). VILIP-1 concentration 
was higher in VaD than in MCI patients (t = -2.063, df = 50, p = 0.044; Figure 1). 
A cut-off level of 116.3 pg/ml for VILIP-1 was determined by Receiver Operator 
Characteristic (ROC) curve analysis. AD patients were differentiated from HC by 62.4% 
sensitivity and 88.9% specificity (AUC = 0.811, p = 0.002; Figure 2A). Fifteen of 43 MCI 
patients had VILIP-1 levels higher than the cut-off value. The VILIP-1/Aβ1-42 ratio 
differentiated AD patients from HC with high sensitivity and specificity (82% sensitivity and 
87.5% specificity, AUC = 0.816, p = 0.004, with VILIP-1/Aβ1-42 cut-off set at 0.0877), as 
well as VILIP-1/p-tau199 ratio (96% sensitivity and 40% specificity, AUC = 0.600, p = 0.464, 
with VILIP-1/p-tau199 cut-off set at 12.71) and VILIP-1/p-tau231 ratio (72.4% sensitivity and 
100% specificity, AUC = 0.772, p = 0.055, with VILIP-1/p-tau231 cut-off set at 63.53). VILIP-
1/p-tau181 and VILIP-1/t-tau ratios showed lower efficiency in differentiating AD patients and 
HC. VILIP-1/p-tau181 ratio differentiated AD patients and HC with 46.6% sensitivity and 
66.7% specificity (AUC = 0.444, p = 0.583) with cut-off set at 1.8022, while VILIP-1/t-tau 
ratio showed 76% sensitivity and 22.2% specificity (AUC = 0.424, p = 0.456) in 
differentiating AD patients from HC with cut-off set at 0.1743 (Figure 2B-F). 
 
VILIP-1 as an index of cognitive decline progression in AD 
AD patients were divided into three groups according to MMSE scores:1) mild AD 
(MMSE 20 - 25), 2) moderate AD (MMSE 10 - 19), and 3) severe AD (MMSE < 10). As only 
one AD patient had a MMSE score below 10, only patients with mild and moderate AD were 
analyzed. There was no significant difference (t = 1.890, df = 106, p = 0.061) in VILIP-1 
levels between patients with mild (161.5 ± 85.3 pg/ml) and moderate AD (130.6± 81 pg/ml; 
Figure 3). Levels of VILIP-1 did not correlate with MMSE scores in the mixed group of AD 
and MCI patients and HC (rS = -0.053, df = 159, p = 0.502). There was a negative correlation 
between VILIP-1/Aβ1-42 ratio and MMSE scores in the mixed group of AD, MCI, and HC 
cases (rS= -0.279, df = 97, p = 0.005; Figure 4A). There was a positive correlation between 
MMSE scores and VILIP-1/t-tau (rS= 0.285, df = 116, p = 0.002; Figure 4B), VILIP-1/p-
tau181 (rS = 0.185, df = 112, p = 0.049; Figure 4C), and VILIP-1/p-tau231 (rS = 0.278, df = 53, 
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p = 0.040; Figure 4D) ratios in the mixed group of AD and MCI patients and HC. There was 
no significant correlation between MMSE scores and VILIP-1/p-tau199 ratio (rS= 0.148, df = 
78, p = 0.189)  
 
VILIP-1 in differentiation of MCI patients with increased risk of AD 
MCI patients were divided into two groups according to the levels of CSF biomarkers 
of AD (t-tau, Aβ1-42, p-tau181,p-tau199, and p-tau231). Cut-off levels were set at 450 pg/ml (t-
tau), 500 pg/ml (Aβ1-42) and 60 pg/ml (p-tau181) according to Humpel [33]. A cut-off level of 
2.58 pg/ml for p-tau199 biomarker was determined on a cohort of 36 AD patients and 15 HC, 
while p-tau231 cut-off level of 1.281 U/ml was determined on a cohort of 34 AD patients and 
17 HC. In order to establish the best possible cut-off values, we wanted to collect as much 
samples as possible. Therefore, the number of AD and HC samples with determined p-
tau199 or p-tau231 and VILIP-1 levels slightly differed (Table 2). Because not all MCI patients 
with determined VILIP-1 levels had all five biomarkers measured, 14, 10, 12, 19 and 22 MCI 
patients in the case Aβ1-42, t-tau, p-tau181,p-tau199, and p-tau231were excluded, respectively. 
MMSE scores and demographic data of MCI patients included in this part of analysis are 
listed in Table 3.  
VILIP-1 CSF levels were significantly higher in MCI patients with Aβ1-42 CSF levels lower 
than the 500 pg/ml cut-off value (8 of 29 MCI patients; t = 2.355, df = 27, p = 0.026; Figure 
5A). There was no difference in VILIP-1 levels between the two groups of MCI patients with 
normal and pathological levels of t-tau (above 450 pg/ml; t = 1.577, df = 32, p = 0.125; 
Figure 5B). By taking into account that t-tau levels differ according to the age of patients, a 
cut-off level of 450 pg/ml was taken in view of the average age of the MCI patients (67 
years), as based on Humpel's recommendations [33]. VILIP-1 levels were significantly higher 
in MCI patients (13 of 32 MCI patients) with pathological levels of p-tau181 (above 60 pg/ml, 
U = 41, Z = -3.252, p =0.001; Figure 5C). VILIP-1 concentration was also significantly 
higher in MCI patients (8 of 21 MCI patients) with pathological levels of p-tau231 (above 
1.281 U/ml; t = 5.839, df = 19, p < 0.001; Figure 5E). Although statistical significance in the 
levels of VILIP-1between MCI patients with normal and pathological levels of p-tau199 was 
not proved, a trend of VILIP-1 increase in the MCI group with pathological levels of p-
tau199was observed (above 2.58 pg/ml, U = 45, Z = -1.838, p = 0.066; Figure 5D). 
A negative correlation was observed between VILIP-1 and Aβ1-42 CSF levels (Figure 
6A; Table 4). The CSF VILIP-1 levels positively correlated with CSF t-tau (Figure 6B; 
Table 4), p-tau181 (Figure 6C; Table 4), p-tau199 (Figure 6D; Table 4) and p-tau231 (Figure 
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6E; Table 4). A correlation between VILIP-1 and AD protein biomarkers was determined 
across the mixed group of AD, MCI and HC cases (Figure 6A-E; Table 4). Additionally, a 
positive correlation between VILIP-1 and t-tau, p-tau181, p-tau199, and p-tau231levels was also 
observed in AD and MCI patients (Table 4). 
The ratios of VILIP-1 to all five biomarkers were also compared between the two 
groups of MCI patients. VILIP-1/Aβ1-42 ratio was significantly higher in MCI patients with 
pathological levels of p-tau231 (Figure 7A; Table 5).The MCI group with pathological levels 
of p-tau231 had significantly higher VILIP-1/p-tau181 ratio (Figure 7D; Table 5). Although 
statistical significance in the VILIP-1/Aβ1-42 ratio between MCI groups with pathological 
levels of p-tau199 and p-tau181 was not proved (Table 5), there was a trend of VILIP-1/Aβ1-42 
ratio increase in the MCI groups with pathological levels of these biomarkers (Figure 7B, C). 
The same trend was observed for the VILIP-1/p-tau181 ratio in MCI group with pathological p-
tau199 levels (Figure 7E) and VILIP-1/p-tau199 ratio in MCI group with pathological p-tau231 
levels (Figure 7F; Table 5).  On the contrary, VILIP-1/p-tau231 ratio increase in MCI group 
with normal levels of Aβ1-42was also observed (Table 5). 
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Discussion 
 
 
In this study we used CSF VILIP-1 levels to differentiate MCI patients into two 
groups: with and without the risk of AD. AD risk groups within the MCI groups of patients 
were defined by the levels of five CSF AD biomarkers (Aβ1-42, t-tau, p-tau181,p-tau199, and p-
tau231). We tested VILIP-1 effectiveness in early detection of AD in MCI patients, and 
confirmed previous observations that VILIP-1 is a useful biomarker in early AD diagnosis 
[12, 17, 27-30]. Additionally, we tested VILIP-1 potential in differentiating AD from other 
primary causes of dementia, and its ability in predicting disease progression. Our results show 
that the levels of VILIP-1 were higher in AD compared to HC and MCI patients. No 
difference in VILIP-1 levels was seen between AD and patients with other dementias. This 
contrasts with the results of Tarawneh et al. [27] who reportedVILIP-1 levels to be prognostic 
of future cognitive decline in early symptomatic AD (Clinical Dementia Rating, CDR 0.5) or 
mild AD (CDR 1) in comparison to non-AD dementia cases. The non-AD dementia group 
from that study was a small cohort of 19 individuals either with FTD, PSP, or LBD [27]. Our 
“other dementia” group consisted of 32 individuals, of whom 9 presented with VaD, 18 with 
FTD, and 5 with LBD. There was no significant difference in VILIP-1 levels between AD and 
either VaD or FTD. VILIP-1 levels were significantly lower in LBD compared to AD. This 
finding agrees with the study of Luo et al. (2013) in whichVILIP-1 levels and VILIP-1/Aβ1–42 
ratios were higher in AD compared to LBD [29]. Altogether, these results indicate that 
VILIP-1 specificity in differentiating AD from other primary causes of dementia is low for 
VaD and marginal for FTD, whereas it does differentiate AD from LBD with 77.1% 
sensitivity and 100% specificity.  
We tested whether there was a correlation between VILIP-1 and other CSF AD biomarkers. 
VILIP-1 levels negatively correlated with Aβ1–42 levels in a mixed group of AD, MCI, and 
HC cases. This was not observed in two previous studies [17, 29]. However, the 
neuroimaging study of Tarawneh et al. [28] showed that VILIP-1 levels and VILIP-1/Aβ1–42 
ratios correlate with amyloid load in the brain as detected by Pittsburgh Compound-B [28]. 
We did not observe VILIP-1 and Aβ1–42 correlation in both AD and MCI patients. Four 
biomarkers (t-tau, p-tau181, p-tau199, and p-tau231) positively correlated with VILIP-1 across 
AD, MCI, and HC cases and also in separate groups of AD and MCI patients. Because the HC 
group was significantly younger than the AD and MCI patients, it was also important to 
demonstrate a correlation of VILIP-1 with AD biomarkers within AD and MCI patients 
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separately. The VILIP-1 correlation with Aβ1–42, t-tau and p-tau181 agrees with previous data 
[17, 29, 30]. Surprisingly, there was no significant difference in VILIP-1 levels between 
patients with mild and moderate AD. Other authors however reported that VILIP-1 levels and 
VILIP-1/Aβ1-42ratio predict cognitive decline in cognitively healthy individuals and AD 
patients [27, 28]. Both parameters predicted conversion of CDR 0 HC group to CDR 0.5 or 
higher [27]. Also, VILIP-1 levels and VILIP-1/Aβ1-42 ratio predicted AD patients likely to 
cognitively decline more rapidly over the follow-up period of 2.6 years [28]. It should be 
taken into account that different neuropsychological tests were used in our and the studies by 
Tarawaneh and colleagues [27, 28]. VILIP-1 levels did not correlate with MMSE scores, but 
the VILIP-1/Aβ1-42ratio negatively correlated with MMSE scores. Additionally, VILIP-1/t-
tau, VILIP-1/p-tau181 and VILIP-1/p-tau231 ratios positively correlated with MMSE scores. 
Thus, our results indicate that possibly in the combination with other biomarkers, VILIP-1 
could be used as a prognostic biomarker of cognitive decline in AD. A recent longitudinal 
study strengthened the notion of VILIP-1 being a prognostic biomarker of AD, and reported 
that VILIP-1 levels increase over time in MCI patients by as much as 10.7 pg/ml per year 
[34]. 
The cut-off level for VILIP-1 of 116.3 pg/ml set in this study was lower than the cut-
off values of other studies (535 pg/ml [27], 560 pg/ml ([28] and 365 pg/ml [17]). Sutphen et 
al. also reported the mean value for VILIP-1 to be around 150 pg/ml in healthy middle-aged 
individuals [12]. The cut-off value of biomarker depends on the ELISA kit used. For example, 
in our previous study we reported that ELISA kits for Aβ1–42 and t-tau from two different 
vendors cannot be used interchangeably [35]. A microplate-based immunoassay (Erenna, 
Singulex, CA) was used in three studies [12, 27, 28], while one study [17] used an in-house 
VILIP-1 ELISA [36]. In the present study we used a VILIP-1 Human ELISA kit (BioVendor). 
Two recent studies in which this kit was also used reported mean VILIP-1 values of 105 
pg/ml, 69 pg/ml, and 42 pg/ml in AD, MCI, and HC, respectively [30], and 72.1 pg/ml and 43 
pg/ml in AD and HC, respectively [29], which corresponds to our results. 
We compared VILIP-1 levels between two groups of MCI patients with and without 
pathological levels of five CSF biomarkers (Aβ1-42, t-tau, p-tau181, p-tau199, and p-tau231). 
VILIP-1 levels were significantly higher in MCI patients with pathological levels of Aβ1-42, p-
tau181, and p-tau231. There was no difference in VILIP-1 levels between MCI groups based on 
levels of p-tau199 and t-tau, although there was a trend of VILIP-1 increase in the MCI group 
with pathological p-tau199 levels. Additionally, we compared VILIP-1/Aβ1-42, VILIP-1/t-tau, 
VILIP-1/p-tau181, VILIP-1/p-tau199, and VILIP-1/p-tau231 ratios between the MCI groups. 
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VILIP-1/Aβ1-42 and VILIP-1/p-tau181 ratios were significantly higher in the MCI groups with 
pathological levels of p-tau231. Finally, there was a trend of increase in the VILIP-1/Aβ1-42 
ratio between MCI groups with pathological levels of p-tau199 and p-tau181 and VILIP-1/p-
tau181 ratio in MCI group with pathological p-tau199 levels. Our results indicate that VILIP-1 
levels alone or in combination with Aβ1-42, t-tau, and p-tau199 (VILIP-1/Aβ1-42, VILIP-1/t-tau, 
VILIP-1/p-tau199) could be used as early biomarkers of AD. However, we recommend 
combination of VILIP-1 with other CSF biomarkers rather than use of VILIP-1 alone.We 
could discriminate two groups of MCI patients by CSF VILIP-1 levels, whose risk for AD 
was defined by their levels of Aβ1-42, t-tau, p-tau181, p-tau199, and p-tau231. It must be kept in 
mind that MCI patients whose CSF samples were analyzed in this cross-sectional study 
should be monitored and these results should be further validated on a larger cohort of MCI 
patients with regular follow-up every 6 months.  
Besides the fact that this study is cross-sectional, the other limitation of this study is 
that our HC group is significantly younger than the AD group. The longitudinal study of 
Sutphen et al. showed that VILIP-1 levels increase with age in healthy individuals, with 
significantly higher levels in late middle age (65-74 years of age) compared with early (45-
54) and mid middle age (55-64 years) in the ε4 allele of apolipoprotein E (APOE) gene non-
carriers and within-person increases over time in late middle age [12]. While baseline levels 
of VILIP-1 in the at-risk ε4 carriers at baseline were not significantly different among those 
age groups, they significantly increased longitudinally within individuals in mid middle age 
compared with the ε4 non-carriers in late middle age [12]. At the same time, the annual mean 
increase in VILIP-1 levels in mid middle age was greater in ε4 carriers compared with ε4 non-
carriers [12]. These and previous results suggest that VILIP-1 should be considered as marker 
of neurodegeneration or neuronal death, comparably to t-tau. For example, major increases in 
t-tau levels have been detected in diseases characterized by extensive neuronal damage, such 
as Creutzfeldt-Jakob disease [37, 38] or stroke [39]. Similarly to t-tau, before being 
considered an AD biomarker, VILIP-1 was used as a marker of acute ischemic stroke [36]. 
Thus, in this study VILIP-1 levels were normalized as a ratio to CSF biomarkers that do not 
fluctuate with the age of a patient (Aβ1-42, p-tau181, p-tau199, and p-tau231) [33]. The VILIP-1/t-
tau ratio was also determined. ROC curve analysis showed that VILIP-1/Aβ1-42 and VILIP-
1/p-tau231 ratios reached the highest values of sensitivity and specificity in differentiating AD 
patients from HC followed by VILIP-1/p-tau199ratio that had higher sensitivity, but lower 
specificity thanVILIP-1 alone. Sensitivities and specificities of VILIP-1 and VILIP-1/Aβ1-42 
ratio observed in this study are high, yet Luo et al. reported even higher values of sensitivity 
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and specificity (78.7% and 87.5% for VILIP-1, 98.4% and 97.5% for VILIP-1/Aβ1-42) [29]. In 
this respect, our results are more similar to those obtained by Lee et al. where 67.9% 
sensitivity and 90.5% specificity was reached in distinguishing AD patients from HC [17]. 
Tarawneh et al. showed that VILIP-1 and VILIP-1/Aβ1-42 ratio differentiated AD group from 
HC with 0.75 AUC (our study 0.832 AUC) and 0.87 AUC (our study 0.820 AUC), 
respectively [27]. 
The results of the present study indicate that VILIP-1 may represent a valuable 
biomarker in addition to Aβ1–42, t-tau and p-tau181in the early diagnosis of AD and in 
differentiating MCI patients with higher risk of progression to AD. In spite of a relatively 
small cohort of patients, comparison of VILIP-1 levels to two other potential AD biomarkers 
(p-tau199 and p-tau231) further supports the use of VILIP-1 as a reliable early AD biomarker. 
We also compared VILIP-1 levels between two MCI groups of patients with and without 
pathological CSF levels of Aβ1–42, t-tau, p-tau181, p-tau199 and p-tau231. CSF biomarker levels 
were used in the definition of AD risk groups among these MCI patients. VILIP-1 levels 
successfully differentiated two MCI groups of patients with normal and pathological levels of 
all CSF biomarkers, except for p-tau199 and t-tau (although there was a trend of VILIP-1 
increase in the MCI group with pathological p-tau199 levels). VILIP-1 in combination with 
Aβ1-42 and p-tau181 (VILIP-1/Aβ1-42, VILIP-1/p-tau181 ratios) also differentiates MCI patients 
with normal and pathological levels of CSF biomarkers. Future studies will provide further 
validation of VILIP-1 diagnostic potential by longitudinal follow-up of MCI patients and 
development of prediction models for MCI progression in AD based on VILIP-1, Aβ1–42, t-
tau, p-tau181, p-tau199, and p-tau231. 
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Table 1. CSF levels of VILIP-1 measured by ELISA, demographic data, and MMSE scores of 
patient groups. Data are presented as mean ± SD and for VILIP-1 levels also as median (25th-
75th percentile). AD – Alzheimer’s disease, MCI – mild cognitive impairment, HC – healthy 
control, VaD – vascular dementia, FTD – frontotemporal dementia, LBD –Lewy body 
disease, MMSE – Mini-Mental State Examination. 
 
 
a
Age significantly different from HC group (t = 7.857, df = 116, p < 0.001). 
b
Age significantly different from HC group (t = -5.002, df = 50, p < 0.001). 
c
Age significantly different from HC group (t = -3.820, df = 39, p < 0.001). 
d
Age significantly different from HC group (t = -2.410, df = 25, p = 0.024). 
 
 
 
 
 
Group 
 
(number of patients) 
VILIP-1 (pg/ml) 
 
Age 
 
Mean ± SD 
Gender 
 
Women vs. Men 
MMSE 
 
Mean ± SD Mean ± SD Median 
(25-75th percentile) 
AD (109) 147.9 ± 84.8 145.5 
(86.4 – 200.7) 
 
72 ± 8.2a 60 vs. 49 20.1 ± 4.6 
MCI (43) 98.7 ± 80.3 77.3 
(27 – 137.5) 
 
68  ± 9.8b 21 vs. 22 24.9  ± 2.9 
HC (9) 65.5 ± 49.3 27 
(27– 112.4) 
 
50 ± 9.8 6 vs. 3 27.7 ± 1.7 
Other dementias (32) 118.1 ± 77.5 99.9 
(48.5 – 181.2) 
 
65 ± 10.1c 11 vs. 21 19.0 ± 5.8 
VaD (9) 157.9± 87.6 167.3 
(70.1 – 221.8) 
 
73 ± 8.6 2 vs. 7 22.4 ± 6.2 
FTD (18) 117.4 ± 71.0 106.5 
(57.7 – 177) 
 
60 ± 10.6d 8 vs. 10 17.2 ± 5.3 
LBD (5) 49 ± 16.2 48 
(33.3 – 65.2) 
71 ± 4.4 1 vs. 4 19.6 ± 4.7 
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Table 2. CSF levels of Aβ1-42, t-tau, p-tau181, p-tau199, and p-tau231 measured by ELISA. Data are presented as mean ± SD and as median (25th-
75th percentile). AD – Alzheimer’s disease, MCI – mild cognitive impairment, HC – healthy control, VaD – vascular dementia, FTD – 
frontotemporal dementia, LBD –Lewy body disease. 
*Not all patients with determined VILIP-1 levels had determined all other CSF biomarkers (Aβ1-42, t-tau, p-tau181, p-tau199 and p-tau231).  
Group 
(number of 
patients with 
determined 
VILIP-1 levels)* 
 
 
Aβ1-42 (pg/ml) 
 
t-tau (pg/ml) p-tau181 (pg/ml) p-tau199 (pg/ml) p-tau231 (U/ml) 
Mean ± SD 
(number of 
patients) 
Median 
(25-75th 
percentile) 
Mean ± SD 
(number of 
patients) 
Median 
(25-75th 
percentile) 
Mean ± SD 
(number of 
patients) 
Median 
(25-75th 
percentile) 
Mean ± SD 
(number of 
patients) 
Median 
(25-75th 
percentile) 
Mean ± SD 
(number of 
patients) 
Median 
(25-75th 
percentile) 
AD 
 (109) 
601.5 ± 308.1 
(61) 
591 
(353.5 – 792.5) 
 
482.2 ± 422.8 
(75) 
399 
(232 – 604) 
 
79.2 ± 42.6 
(73) 
69 
(56 – 95.5) 
 
3.860 ± 3.129 
(50) 
3.080 
(1.295 – 5.625) 
 
6.955 ± 7.324 
(29) 
3.347 
(1.346 – 12.825) 
 
MCI  
(43) 
761 ± 365.9 
(30) 
721.5 
(478.8 – 1046.5) 
 
255.4 ± 174.4 
(34) 
210.5 
(145.5 – 332.3) 
 
61.6 ± 35.1 
(32) 
52.1 
(38.1 – 71.9) 
 
2.695 ± 1.753 
(25) 
2.500 
(1.245 – 4.600) 
 
3.070 ± 4.661 
(21) 
0.910 
(0.431 – 2.760) 
 
HC  
(9) 
922.6 ± 397 
(8) 
963.5 
(616.3 – 1277.5) 
 
160.4 ± 98.1 
(9) 
157 
(72.5 – 264.5) 
 
33.5 ± 23.2 
(9) 
18 
(15.9 – 57.3) 
 
1.698 ± 1.002 
(5) 
1.660 
(0.750 – 2.665) 
 
0.606 ± 0.539 
(5) 
0.360 
(0.344 – 0.992) 
 
VaD 
(9) 
NA NA 590 ± 333.3 
(4) 
630.5 
(263.8 – 876.7) 
 
86.4 ± 33.8 
(4) 
86.1 
(53.8 – 119.3) 
 
NA NA NA NA 
FTD  
(18) 
598 ± 243.2 
(2) 
598 
(426 – 770) 
 
526.8 ± 311.7 
(14) 
463.7 
(234.7 – 790.8) 
 
77.9 ± 33.2 
(15) 
80.3 
(42.6 – 109.4) 
 
3.151 ± 3.062 
(6) 
2.745 
(0.157 – 6.277) 
 
4.788 ± 4.067 
(3) 
3.090 
(1.846 – 9.43) 
 
LBD  
(5) 
NA NA 114.1 ± 28.3 
(4) 
115.7 
(86.1 – 140.5) 
 
49.4 ± 37.7 
(4) 
33.1 
(27.3 – 87.9) 
 
NA NA NA NA 
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Table 3. MMSE scores and demographic data of AD, MCI and HC patients with determined 
levels of VILIP-1 and one of the five biomarkers (Aβ1-42 ,t-tau, p-tau181, p-tau199 or p-tau231). 
Data are presented as mean ± SD. 
 
 
  
  Age 
Mean ± SD 
Gender 
Women vs. Men 
MMSE 
Mean ± SD 
 
Aβ1-42 and VILIP-1 
 
AD (61) 
 
72 ± 7.2 
 
32 vs. 29 
 
19.2 ± 4.5 
MCI (29) 67  ± 11.1 14 vs. 15 24.4  ± 3.2 
HC (8) 
 
48 ± 9.2 5 vs. 3 27.4 ± 1.6 
 
t-tau and VILIP-1 
 
AD (75) 
 
73 ± 7.7 
 
37 vs. 38 
 
19.3 ± 4.4 
MCI (34) 68  ± 10.3 16 vs. 18 24.5  ± 3.0 
HC (9) 
 
50 ± 9.8 6 vs. 3 27.7 ± 1.7 
 
p-tau181 and VILIP-1 
 
AD (73) 
 
72 ± 8.1 
 
37 vs. 36 
 
19.3 ± 4.8 
MCI (32) 67  ± 10.5 15 vs. 17 24.7  ± 2.9 
HC (9) 
 
50 ± 9.8 6 vs. 3 27.7 ± 1.7 
 
p-tau199 and VILIP-1 
 
AD (50) 
 
73 ± 6.5 
 
27 vs. 23 
 
19.2 ± 4.6 
MCI (25) 67  ± 11.5 14 vs. 11 24.5  ± 3.1 
HC (5) 
 
44 ± 19.1 4 vs. 1 27 ± 1.9 
 
p-tau231 and VILIP-1 
 
AD (29) 
 
72 ± 7.3 
 
18 vs. 11 
 
18.7 ± 4.2 
MCI (21) 69 ± 11.5 11 vs. 10 24.4  ± 3.0 
HC (5) 
 
44 ± 10.1 4 vs. 1 27.0 ± 1.9 
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Table 4. Correlations between VILIP-1 and five biomarkers across the mixed group of AD, 
MCI, and HC cases, and in AD and MCI patients. 
 
*Groups without a normal distribution were correlated by Spearman’s correlation. 
 Correlation between VILIP-1 and CSF biomarkers 
 
 
 
Aβ1-42 and VILIP-1 
 
AD (61), MCI (29) and HC (8) 
 
(r=-0.225,df=96, p=0.026) 
AD (61) (r=-0.086,df=59, p=0.510) 
MCI (29) (r=-0.317,df=27, p=0.093) 
 
 
 
 
t-tau and VILIP-1 
 
 
AD (75), MCI (34) and HC (9) 
 
(rS=0.419,df=116, p<0.001)* 
AD (75) (rS =0.363,df=73, p=0.001)* 
MCI (34) (r=0.338,df=32, p=0.051) 
 
 
 
 
p-tau181 and VILIP-1 
 
 
AD (73), MCI (32) and HC (9) 
 
(rS=0.679,df=112, p<0.001)* 
AD (73) (r=0.554,df=71, p<0.001) 
MCI (32) (r=0.688,df=30, p<0.001) 
 
 
 
 
p-tau199 and VILIP-1 
 
 
AD (50), MCI (25) and HC (5) 
 
(rS =0.514,df=78, p<0.001)* 
AD (50) (r=0.683,df=48, p<0.001) 
MCI (25) 
 
(r=0.489,df=23, p=0.013) 
 
 
 
p-tau231 and VILIP-1 
 
 
AD (29), MCI (21) and HC (5) 
 
(rS =0.712,df=53, p<0.001)* 
AD (29) (rS =0.492,df=27, p=0.007)* 
MCI (21) (rS=0.788,df=19, p<0.001)* 
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Table 5. Comparison of VILIP-1 and Aβ1-42, t-tau, p-tau181, p-tau199, and p-tau231 ratios between MCI patients with normal and pathological 
levels of five biomarkers (Aβ1-42, t-tau, p-tau181, p-tau199, and p-tau231). 
 
MCI 
group  
VILIP-1/Aβ1-42 VILIP1/t-tau 
 
VILIP-1/p-tau181 VILIP-1/p-tau199 VILIP-1/p-tau231 
Aβ1-42  (U=54, Z=-1.464, p=0.143) (U=54, Z=-0.525, p=0.600) (U = 35, Z=-0.889, p=0.374) (U=9, Z=-2.803, p=0.005)* 
t-tau (U=20, Z=-0.385, p=0.700)  (U=58, Z=-0.493, p=0.622) (U=26, Z=-0.585, p=0.558) (U=3, Z=-1.156, p=0.248) 
p-tau181 (U=48, Z=-1.858, p=0.063) (U=93, Z=-1.170, p=0.242)  (U=61, Z=-0.248, p= 0.804) (U=26, Z=-1.486, p=0.137) 
p-tau199 (U=44, Z=-1.593, p=0.111) (U=51, Z=-1.469, p=0.142) (U=42, Z=-1.426, p=0.154)  (U=37, Z=-0.983, p=0.326) 
p-tau231 (U=3, Z=-3.549, p<0.001)* (U=51, Z=-0.072, p=0.942 (U=12, Z=-2.368, p = 0.018)* (U=21, Z=-1.941, p=0.052)  
 
*Statistically significant at p<0.05. 
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Figure1. CSF VILIP-1 levels in AD, MCI, HC, FTD, and LBD patients, measured by ELISA. 
Patients with FTD, VaD, and LBD are also grouped as other dementias. Boxes represent the 
median, the 25th and 75th percentiles, and bars indicate the range of data distribution. 
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Figure 2. Receiver Operator Characteristic (ROC) curve analysis for A) VILIP-1, B) VILIP-
1/Aβ1-42 ratio, C) VILIP-1/t-tau ratio, D) VILIP-1/p-tau181 ratio, E) VILIP-1/p-tau199 ratio, and 
F) VILIP-1/p-tau231 ratio. 
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Figure 3. CSF VILIP-1 levels in patients with mild (161.5 ± 85.3pg/ml) and moderate 
(130.6± 81pg/ml) AD. There were 64 patients with mild AD and 44 patients with moderate 
AD. Boxes represent the median, the 25th and 75th percentiles, and bars indicate the range of 
data distribution. 
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Figure 4. Correlation of MMSE scores and CSF VILIP-1/Aβ1-42 ratio (rS= -0.279, p = 0.005), 
VILIP-1/t-tau ratio (rS= 0.285, p = 0.002), VILIP-1/p-tau181 ratio (rS= 0.185, p = 0.049) and 
VILIP-1/p-tau231 ratio (rS= 0.278, p = 0.040). Dotted lines represent 95% confidence intervals 
(CI) for r value. 
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Figure 5. CSF VILIP-1 levels between MCI patients with pathological and normal levels of 
A) Aβ1-42 (cut-off = 500 pg/ml), B) t-tau (cut-off = 450 pg/ml), C) p-tau181 (cut-off = 60 
pg/ml), D) p-tau199 (cut-off = 2.58 pg/ml), and E) p-tau231 (cut-off = 1.281U/ml). Boxes 
represent the median, the 25th and 75th percentiles, and bars indicate the range of data 
distribution. The black dot in B represents an outlier. 
*Statistically significant at p<0.05. 
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Figure 6. Correlation of CSF VILIP-1 and CSF A) Aβ1-42 (r = -0.225, p = 0.026), B) t-tau (rS 
= 0.419, p < 0.001), C) p-tau181 (rS = 0.679, p < 0.001), D) p-tau199 (rS = 0.514, p < 0.001) and 
E) p-tau231 (rS = 0.712, p < 0.001). Dotted lines represent 95% confidence intervals (CI) for r 
value.  
 
Figure 7. VILIP-1/Aβ1-42 ratio between MCI patients with pathological and normal levels of 
A) p-tau231 (cut-off = 1.281 U/ml), B) p-tau199 (cut-off = 2.58 pg/ml), C)p-tau181 (cut-off = 60 
pg/ml). VILIP-1/p-tau181 ratio between MCI patients with pathological and normal levels of 
D) p-tau231 and E) p-tau199. VILIP-1/p-tau199 ratio between MCI patients with pathological and 
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normal levels of E) p-tau231. Boxes represent the median, the 25th and 75th percentiles, and 
bars indicate the range of data distribution. 
*Statistically significant at p<0.05. 
 
